Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 185 articles:
HTML format
Text format



Single Articles


    April 2017
  1. HANNA WM, Slodkowska E, Lu FI, Nafisi H, et al
    Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
    J Clin Oncol. 2017 Apr 26:JCO2016705319. doi: 10.1200/JCO.2016.70.5319.
    PubMed     Text format     Abstract available


  2. URRUTICOECHEA A, Rizwanullah M, Im SA, Ruiz ACS, et al
    Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Th
    J Clin Oncol. 2017 Apr 24:JCO2016706267. doi: 10.1200/JCO.2016.70.6267.
    PubMed     Text format     Abstract available


  3. MALY RC, Liang LJ, Liu Y, Griggs JJ, et al
    Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors.
    J Clin Oncol. 2017 Apr 18:JCO2016689497. doi: 10.1200/JCO.2016.68.9497.
    PubMed     Text format     Abstract available


  4. AHN S, Port ER
    Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement.
    J Clin Oncol. 2017 Apr 14:JCO2017728816. doi: 10.1200/JCO.2017.72.8816.
    PubMed     Text format    


  5. KURIAN AW, Li Y, Hamilton AS, Ward KC, et al
    Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Apr 12:JCO2016716480. doi: 10.1200/JCO.2016.71.6480.
    PubMed     Text format     Abstract available


  6. BLUM JL, Flynn PJ, Yothers G, Asmar L, et al
    Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
    J Clin Oncol. 2017 Apr 11:JCO2016714147. doi: 10.1200/JCO.2016.71.4147.
    PubMed     Text format     Abstract available


  7. BORGQUIST S, Giobbie-Hurder A, Ahern TP, Garber JE, et al
    Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
    J Clin Oncol. 2017;35:1179-1188.
    PubMed     Text format     Abstract available


    March 2017
  8. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    PubMed     Text format     Abstract available


  9. BARDIA A, Mayer IA, Diamond JR, Moroose RL, et al
    Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2017 Mar 14:JCO2016708297. doi: 10.1200/JCO.2016.70.8297.
    PubMed     Text format     Abstract available


  10. SONNENBLICK A, Agbor-Tarh D, Bradbury I, Di Cosimo S, et al
    Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 13:JCO2016697722. doi: 10.1200/JCO.2016.69.7722.
    PubMed     Text format     Abstract available


    February 2017
  11. HUMMEL SB, van Lankveld JJ, Oldenburg HS, Hahn DE, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2017 Feb 27:JCO2016696021. doi: 10.1200/JCO.2016.69.6021.
    PubMed     Text format     Abstract available


    January 2017
  12. SYMMANS WF, Wei C, Gould R, Yu X, et al
    Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    J Clin Oncol. 2017 Jan 30:JCO2015631010. doi: 10.1200/JCO.2015.63.1010.
    PubMed     Text format     Abstract available


  13. LOIBL S, Denkert C
    How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
    J Clin Oncol. 2017 Jan 30:JCO2016713503. doi: 10.1200/JCO.2016.71.3503.
    PubMed     Text format    


  14. SMITH I, Yardley D, Burris H, De Boer R, et al
    Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluat
    J Clin Oncol. 2017 Jan 23:JCO2016692871. doi: 10.1200/JCO.2016.69.2871.
    PubMed     Text format     Abstract available


  15. CHERAGHI Z, Ayubi E, Doosti-Irani A
    Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: Methodologic Issues to Avoid Misinterpretation in the Meta-Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016710715. doi: 10.1200/JCO.2016.71.0715.
    PubMed     Text format    


  16. HOLMES MD, Wang J, Hankinson SE, Tamimi RM, et al
    Protein Intake and Breast Cancer Survival in the Nurses' Health Study.
    J Clin Oncol. 2017;35:325-333.
    PubMed     Text format     Abstract available


  17. SUPPLI NP, Johansen C, Kessing LV, Toender A, et al
    Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study.
    J Clin Oncol. 2017;35:334-342.
    PubMed     Text format     Abstract available


  18. VAN DEN BOGAARD VA, Ta BD, van der Schaaf A, Bouma AB, et al
    Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.
    J Clin Oncol. 2017 Jan 17:JCO2016698480. doi: 10.1200/JCO.2016.69.8480.
    PubMed     Text format     Abstract available


  19. RECHT A
    Radiation-Induced Heart Disease After Breast Cancer Treatment: How Big a Problem, and How Much Can-and Should-We Try to Reduce It?
    J Clin Oncol. 2017 Jan 17:JCO2016714113. doi: 10.1200/JCO.2016.71.4113.
    PubMed     Text format    


  20. DEL MASTRO L
    Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Jan 17:JCO2016682393. doi: 10.1200/JCO.2016.68.2393.
    PubMed     Text format    


  21. PEREZ EA, Barrios C, Eiermann W, Toi M, et al
    Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    J Clin Oncol. 2017;35:141-148.
    PubMed     Text format     Abstract available


  22. MEGGETTO O, Maunsell E, Chlebowski R, Goss P, et al
    Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
    J Clin Oncol. 2017 Jan 9:JCO2016688895.
    PubMed     Text format     Abstract available


  23. ELLIS MJ, Suman VJ, Hoog J, Goncalves R, et al
    Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    J Clin Oncol. 2017 Jan 3:JCO2016694406.
    PubMed     Text format     Abstract available


  24. FARIAS AJ, Du XL
    Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    J Clin Oncol. 2017;35:86-95.
    PubMed     Text format     Abstract available


    December 2016
  25. CUZICK J, Brentnall AR, Segal C, Byers H, et al
    Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
    J Clin Oncol. 2016 Dec 28:JCO2016698944.
    PubMed     Text format     Abstract available


  26. CHLEBOWSKI RT
    Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention.
    J Clin Oncol. 2016 Dec 28:JCO2016709386.
    PubMed     Text format    


  27. JANELSINS MC, Heckler CE, Peppone LJ, Kamen C, et al
    Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
    J Clin Oncol. 2016 Dec 28:JCO2016685856.
    PubMed     Text format     Abstract available


  28. KIM HS, Umbricht CB, Illei PB, Cimino-Mathews A, et al
    Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
    J Clin Oncol. 2016;34:4390-4397.
    PubMed     Text format     Abstract available


  29. FREEDMAN RA, Foster JC, Seisler DK, Lafky JM, et al
    Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.
    J Clin Oncol. 2016 Dec 19:JCO2016694182.
    PubMed     Text format     Abstract available


  30. JIRALERSPONG S, Goodwin PJ
    Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.
    J Clin Oncol. 2016;34:4203-4216.
    PubMed     Text format     Abstract available


    November 2016
  31. ALFANO CM, Peng J, Andridge RR, Lindgren ME, et al
    Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
    J Clin Oncol. 2016 Nov 28:JCO2016671883.
    PubMed     Text format     Abstract available


  32. VISVANATHAN K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, et al
    Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
    J Clin Oncol. 2016 Nov 21:JCO2015662080.
    PubMed     Text format     Abstract available


  33. WALLNER LP, Abrahamse P, Uppal JK, Friese CR, et al
    Involvement of Primary Care Physicians in the Decision Making and Care of Patients With Breast Cancer.
    J Clin Oncol. 2016;34:3969-3975.
    PubMed     Text format     Abstract available


  34. JHAVERI K
    MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future.
    J Clin Oncol. 2016 Nov 14:JCO2016702712.
    PubMed     Text format    


    October 2016
  35. ZARDAVAS D, Suter TM, Van Veldhuisen DJ, Steinseifer J, et al
    Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stud
    J Clin Oncol. 2016 Oct 23:JCO2015657916. doi: 10.1200/JCO.2015.65.7916.
    PubMed     Text format     Abstract available


    August 2016
  36. PRESS MF, Sauter G, Buyse M, Fourmanoir H, et al
    HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
    J Clin Oncol. 2016 Aug 29. pii: JCO666693.
    PubMed     Text format     Abstract available


  37. COPUR MS, Ramaekers R, Gauchan D, Norvell M, et al
    Recent ASCO Guideline on the Use of Biomarkers for Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
    J Clin Oncol. 2016 Aug 22. pii: JCO682385.
    PubMed     Text format    


  38. SGROI DC, Brufsky A
    Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions.
    J Clin Oncol. 2016 Aug 22. pii: JCO672949.
    PubMed     Text format    


  39. BRADBURY AR, Patrick-Miller L, Schwartz LA, Egleston BL, et al
    Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History.
    J Clin Oncol. 2016 Aug 22. pii: JCO663450.
    PubMed     Text format     Abstract available


  40. MAYER EL, Burstein HJ
    Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    J Clin Oncol. 2016 Aug 22. pii: JCO684068.
    PubMed     Text format    


  41. HASEGAWA T, Uno H, Wei LJ
    How To Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
    J Clin Oncol. 2016 Aug 9. pii: JCO672055.
    PubMed     Text format    


  42. PARTRIDGE AH, Hughes ME, Warner ET, Ottesen RA, et al
    Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
    J Clin Oncol. 2016 Aug 1. pii: JCO658013.
    PubMed     Text format     Abstract available


    July 2016
  43. BAIK SH, Gallo LC, Wells KJ
    Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review.
    J Clin Oncol. 2016 Jul 25. pii: JCO675454.
    PubMed     Text format     Abstract available


  44. GUENANCIA C, Lefebvre A, Cardinale D, Yu AF, et al
    Obesity as a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Jul 25. pii: JCO674846.
    PubMed     Text format     Abstract available


  45. STRULOV SHACHAR S, Hurria A, Muss HB
    Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
    J Clin Oncol. 2016 Jul 18. pii: JCO688242.
    PubMed     Text format    


  46. LAURING J, Wolff AC
    Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.
    J Clin Oncol. 2016 Jul 5. pii: JCO684720.
    PubMed     Text format    


    June 2016
  47. COLLEONI M, Gray KP, Gelber S, Lang I, et al
    Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
    J Clin Oncol. 2016 Jun 20. pii: JCO656595.
    PubMed     Text format     Abstract available


  48. JOHANNSEN M, O'Connor M, O'Toole MS, Jensen AB, et al
    Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Jun 20. pii: JCO650770.
    PubMed     Text format     Abstract available


  49. SCHMIDT MK, Hogervorst F, van Hien R, Cornelissen S, et al
    Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    J Clin Oncol. 2016 Jun 6. pii: JCO665844.
    PubMed     Text format     Abstract available


  50. FRIBBENS C, O'Leary B, Kilburn L, Hrebien S, et al
    Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    J Clin Oncol. 2016 Jun 6. pii: JCO673061.
    PubMed     Text format     Abstract available


    May 2016
  51. LENGACHER CA, Reich RR, Paterson CL, Ramesar S, et al
    Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Clin Oncol. 2016 May 31. pii: JCO657874.
    PubMed     Text format     Abstract available


  52. LIVI L, Meattini I, Kaidar-Person O, Poortmans PM, et al
    Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology.
    J Clin Oncol. 2016 May 23. pii: JCO664276.
    PubMed     Text format    


  53. HINDIE E, Groheux D
    Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection.
    J Clin Oncol. 2016 May 23. pii: JCO674531.
    PubMed     Text format    


  54. RUGO HS, Rumble RB, Macrae E, Barton DL, et al
    Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
    J Clin Oncol. 2016 May 23. pii: JCO671487.
    PubMed     Text format     Abstract available


  55. KUERER HM
    Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer.
    J Clin Oncol. 2016 May 23. pii: JCO668046.
    PubMed     Text format    


  56. JONES LW, Habel LA, Weltzien E, Castillo A, et al
    Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.
    J Clin Oncol. 2016 May 23. pii: JCO656603.
    PubMed     Text format     Abstract available


  57. WOLMARK N, Mamounas EP, Baehner FL, Butler SM, et al
    Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/
    J Clin Oncol. 2016 May 23. pii: JCO626630.
    PubMed     Text format     Abstract available


  58. EKHOLM M, Bendahl PO, Ferno M, Nordenskjold B, et al
    Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.
    J Clin Oncol. 2016 May 9. pii: JCO656272.
    PubMed     Text format     Abstract available


  59. MCCARTHY AM, Bristol M, Domchek SM, Groeneveld PW, et al
    Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO660019.
    PubMed     Text format     Abstract available


  60. ACCORDINO MK, Wright JD, Vasan S, Neugut AI, et al
    Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO666313.
    PubMed     Text format     Abstract available


  61. CHECK DK, Samuel CA, Rosenstein DL, Dusetzina SB, et al
    Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO648162.
    PubMed     Text format     Abstract available


  62. NANDA R, Chow LQ, Dees EC, Berger R, et al
    Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
    J Clin Oncol. 2016 May 2. pii: JCO648931.
    PubMed     Text format     Abstract available


  63. DICKLER MN, Barry WT, Cirrincione CT, Ellis MJ, et al
    Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
    J Clin Oncol. 2016 May 2. pii: JCO661595.
    PubMed     Text format     Abstract available


  64. AXILBUND JE
    Panel Testing Is Not a Panacea.
    J Clin Oncol. 2016;34:1433-5.
    PubMed     Text format    


    April 2016
  65. RAYSON D
    White Knuckling.
    J Clin Oncol. 2016;34:1419-20.
    PubMed     Text format    


  66. HART V, Sprague BL, Lakoski SG, Hampton JM, et al
    Trends in Health-Related Quality of Life After a Diagnosis of Ductal Carcinoma In Situ.
    J Clin Oncol. 2016;34:1323-9.
    PubMed     Text format     Abstract available


  67. DENDULURI N, Somerfield MR, Eisen A, Holloway JN, et al
    Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer
    J Clin Oncol. 2016 Apr 18. pii: JCO670182.
    PubMed     Text format     Abstract available


  68. THAVENDIRANATHAN P, Abdel-Qadir H, Fischer HD, Camacho X, et al
    Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
    J Clin Oncol. 2016 Apr 18. pii: JCO651505.
    PubMed     Text format     Abstract available


  69. REEDER-HAYES K, Peacock Hinton S, Meng K, Carey LA, et al
    Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.
    J Clin Oncol. 2016 Apr 11. pii: JCO658716.
    PubMed     Text format     Abstract available


  70. CARMONA R, Zakeri K, Green G, Hwang L, et al
    Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.
    J Clin Oncol. 2016;34:1270-7.
    PubMed     Text format     Abstract available


  71. SMITH GL
    Toward Minimizing Overtreatment and Undertreatment of Ductal Carcinoma In Situ in the United States.
    J Clin Oncol. 2016;34:1172-4.
    PubMed     Text format    


  72. REGAN MM, Francis PA, Pagani O, Fleming GF, et al
    Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
    J Clin Oncol. 2016 Apr 4. pii: JCO643171.
    PubMed     Text format     Abstract available


  73. WARNER E
    A Rosier Picture for Young Women With Breast Cancer.
    J Clin Oncol. 2016 Apr 4. pii: JCO666073.
    PubMed     Text format    


    March 2016
  74. GATZA ML, Carey LA
    Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer.
    J Clin Oncol. 2016 Mar 28. pii: JCO663872.
    PubMed     Text format    


  75. LESI G, Razzini G, Musti MA, Stivanello E, et al
    Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT).
    J Clin Oncol. 2016 Mar 28. pii: JCO632893.
    PubMed     Text format     Abstract available


  76. RIBI K, Luo W, Bernhard J, Francis PA, et al
    Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
    J Clin Oncol. 2016 Mar 28. pii: JCO648675.
    PubMed     Text format     Abstract available


  77. MULLOOLY M, Pfeiffer RM, Heckman-Stoddard BM, Perloff M, et al
    Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.
    J Clin Oncol. 2016 Mar 28. pii: JCO644492.
    PubMed     Text format    


  78. KING TA, Lyman JP, Gonen M, Voci A, et al
    Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
    J Clin Oncol. 2016 Mar 21. pii: JCO631960.
    PubMed     Text format     Abstract available


  79. GOETZ MP, Suman VJ
    Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO662312.
    PubMed     Text format    


  80. HENRY NL, Somerfield MR, Abramson VG, Allison KH, et al
    Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
    J Clin Oncol. 2016 Mar 21. pii: JCO658609.
    PubMed     Text format     Abstract available


  81. HILDEBRANDT MG, Gerke O, Baun C, Falch K, et al
    [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    J Clin Oncol. 2016 Mar 21. pii: JCO635185.
    PubMed     Text format     Abstract available


  82. REINERT T, Barrios CH
    Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO660803.
    PubMed     Text format    


  83. JASEM J, Amini A, Rabinovitch R, Borges VF, et al
    21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
    J Clin Oncol. 2016 Mar 21. pii: JCO650887.
    PubMed     Text format     Abstract available


  84. PARK JH, Anderson WF, Gail MH
    Reply to L.A. Newman.
    J Clin Oncol. 2016;34:1014-5.
    PubMed     Text format    


  85. ELKIN EB, Hudis CA
    Reply to L.A. Newman.
    J Clin Oncol. 2016;34:1015.
    PubMed     Text format    


  86. SCHMID P, Pinder SE, Wheatley D, Macaskill J, et al
    Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO639179.
    PubMed     Text format     Abstract available


  87. AALDERS KC, Postma EL, Strobbe LJ, van der Heiden-van der Loo M, et al
    Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO643536.
    PubMed     Text format     Abstract available


  88. TUNG N, Lin NU, Kidd J, Allen BA, et al
    Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO650747.
    PubMed     Text format     Abstract available


  89. PAPAKONSTANTINOU A, Foukakis T, Rodriguez-Wallberg KA, Bergh J, et al
    Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
    J Clin Oncol. 2016 Mar 7. pii: JCO653493.
    PubMed     Text format     Abstract available


  90. PARKER BA, Pierce JP
    Importance of Smoking Cessation to Reduce Breast Cancer Mortality.
    J Clin Oncol. 2016 Mar 7. pii: JCO660910.
    PubMed     Text format    


  91. AHN S, Port ER
    Lymphedema Precautions: Time to Abandon Old Practices?
    J Clin Oncol. 2016;34:655-8.
    PubMed     Text format     Abstract available


    February 2016
  92. DESMEDT C, Zoppoli G, Gundem G, Pruneri G, et al
    Genomic Characterization of Primary Invasive Lobular Breast Cancer.
    J Clin Oncol. 2016 Feb 29. pii: JCO640334.
    PubMed     Text format     Abstract available


  93. RUDDY KJ, Risendal BC, Garber JE, Partridge AH, et al
    Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.
    J Clin Oncol. 2016;34:539-41.
    PubMed     Text format    


  94. BURSTEIN HJ, Lacchetti C, Anderson H, Buchholz TA, et al
    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
    J Clin Oncol. 2016 Feb 16. pii: JCO659573.
    PubMed     Text format     Abstract available


  95. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    J Clin Oncol. 2016 Feb 16. pii: JCO633594.
    PubMed     Text format     Abstract available


  96. HARRIS LN, Ismaila N, McShane LM, Andre F, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2016 Feb 8. pii: JCO652289.
    PubMed     Text format     Abstract available


  97. LEYLAND-JONES B, Bondarenko I, Nemsadze G, Smirnov V, et al
    A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
    J Clin Oncol. 2016 Feb 8. pii: JCO635649.
    PubMed     Text format     Abstract available


  98. FREEDMAN RA, Gelman RS, Wefel JS, Melisko ME, et al
    Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    J Clin Oncol. 2016 Feb 1. pii: JCO630343.
    PubMed     Text format     Abstract available


  99. VAN LEEUWEN FE, Ronckers CM
    Anthracyclines and Alkylating Agents: New Risk Factors for Breast Cancer in Childhood Cancer Survivors?
    J Clin Oncol. 2016 Feb 1. pii: JCO650465.
    PubMed     Text format    


  100. DANG CT, Yu AF, Jones LW, Liu J, et al
    Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter.
    J Clin Oncol. 2016 Feb 1. pii: JCO645515.
    PubMed     Text format    


    January 2016
  101. LEE CK, Davies L, Gebski VJ, Lord SJ, et al
    Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
    J Clin Oncol. 2016 Jan 25. pii: JCO624767.
    PubMed     Text format     Abstract available


  102. CAUDLE AS, Yang WT, Krishnamurthy S, Mittendorf EA, et al
    Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    J Clin Oncol. 2016 Jan 25. pii: JCO640094.
    PubMed     Text format     Abstract available


  103. PASSARELLI MN, Newcomb PA, Hampton JM, Trentham-Dietz A, et al
    Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases.
    J Clin Oncol. 2016 Jan 25. pii: JCO639328.
    PubMed     Text format     Abstract available


  104. HRYNIUK W, Jenkins I, Djuric Z
    Psychiatric Disorders Impeding Weight Loss in Obese Breast Cancer Survivors.
    J Clin Oncol. 2016 Jan 25. pii: JCO655639.
    PubMed     Text format    


  105. YOO W, Ansa BE, Coughlin SS, Whitehead MS, et al
    Determinants of adherence to physical activity guidelines among overweight and obese African American breast cancer survivors: Implications for intervention approach.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  106. CLEMONS MJ, Mazzarello S, Vandermeer L, Jones L, et al
    Weight control strategies in breast cancer patients: A systematic review.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  107. HARRIGAN M, Cartmel B, Playdon M, Zhou Y, et al
    Effect of weight history on ability to lose weight after a 6-month randomized controlled weight loss trial in overweight breast cancer survivors: The Lifestyle, Exercise and Nutrition (LEAN) study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  108. BARRY WT, Ruddy KJ, Greaney M, Rosenberg SM, et al
    Impact of Young and Strong on physical activity in young breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  109. HADDAD N, Schnyer R, Neri E, Packer MM, et al
    Moderators of acupuncture effectiveness in breast cancer survivors: Randomized clinical trial (RCT).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  110. CHAMPION V
    Examining the relationship between social cognitive processing and depressive symptoms in long-term breast cancer survivors and their partners.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  111. LEE S, Bae SY, Lee JE, Kim SW, et al
    Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  112. SILVA HC, Mapp G, Terrell D
    Implementation of distress screening for breast cancer patients.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  113. BERYL L, Gillespie K, Rendle K, May SG, et al
    "Hot Girls Pearls" and other coping strategies for women experiencing adverse effects from endocrine therapy in the treatment of breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  114. COHEE AA, Monahan P, Stump TE, Miller K, et al
    Quality of life difficulties in partners of young breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  115. ANSA BE, Yoo W, Whitehead MS, Coughlin SS, et al
    Breast cancer recurrence risk-reduction beliefs and behaviors among African American breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  116. ROCK CL, Sedjo RL, Toriola A, Liu J, et al
    Changes in biomarkers and DNA methylation in breast cancer survivors enrolled in the ENERGY weight loss trial: A pilot study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  117. LIN JJ, Franco R, Egorova N
    Breast cancer: Does where you get treated affect survival?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  118. YEAHIA R, Korenstein D
    The evidence base in support of breast cancer surveillance guidelines: Flying without a net?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  119. LEE J, Kim Z, Lee MH, Lee I, et al
    Development of second primary cancers in breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  120. GONZALES FA, Shariff-Marco S, Dwyer LA, Nuru-Jeter A, et al
    Discrimination and quality of life among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  121. BALLARD A
    Exploring factors influencing sexual satisfaction among breast cancer survivors: The role of sexual communication.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  122. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
    Association of anxiety and depressive symptoms with differing needs among recent breast cancer (BC) survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  123. CHEN SP, Horng CF, Hsieh LL, Hsu KH, et al
    A randomized controlled study for the long term follow-up of breast cancer survivors: A primary care physician (PCP) coordinated care delivery model.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  124. PACKER MM, George H, Koopman C, Innominato PF, et al
    Associations between morning-evening chronotype, fatigue, and QOL in breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  125. MUSTAFA ALI MK, Moeller M, Rybicki LA
    Timing of the survivorship visit and symptom prevalence in breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  126. DE RIDDER M, Lamote J, Fontaine C, Van Parijs H, et al
    Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  127. PAUL E, Yang GJ, Phillips S, Bowles J, et al
    A new paradigm for patient-centered breast cancer care.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  128. VICINI FA
    The increasing role of breast cancer lymphedema screening, diagnosis, and management as part of evidence-based breast cancer survivorship.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  129. MERRIMAN J, Gentry A, Ahrendt GM, Brufsky A, et al
    Predictors of trajectories of cognitive change in women with breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  130. SATPUTE SR
    Systematic development of a a breast cancer survivorship program at a small independent oncology practice.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  131. SINHA AK, Hsu L, Patangan M, Le-Petross HT, et al
    Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  132. FONTAINE C, Vanhoeij M, Lamote J, De Greve J, et al
    The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  133. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
    Patient-reported outcomes (PROs), unmet need, and psychosocial adaptation among recent breast cancer (BC) survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  134. ESSER M, Singh N, Rowe J, McCann M, et al
    Measuring knowledge gained for young breast cancer survivors and co-survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  135. GUGLIELMINO J, Labban JD, Rugo HS, Anders CK, et al
    Emotional/psychological characteristics of women diagnosed with breast cancer following treatment: Participation versus nonparticipation in survivorship programs.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  136. KHOSLA P, Molnar J, Corona ME, Garcia SM, et al
    Improving patient participation in a breast cancer survivorship program at a safety net hospital.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  137. CORRELL JA, Peterson LL
    Psychosocial well-being assessment in women with breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  138. GROEN WG, Oldenburg HS, Wouters MW, Aaronson NK, et al
    Evaluation of an interactive portal for breast cancer survivors: Use, satisfaction, and preliminary effects.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  139. ROSENBERG SM, Gelber SI, Ruddy KJ, Morgan E, et al
    Post-traumatic stress disorder in young breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  140. MCDOWELL K, Brown S, Serrano M, Lai LL, et al
    Evaluating a clinically and culturally informed survivorship care plan trial for African American breast cancer survivors (AABCS).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  141. YEE S, Glass K, Foong S, Kennedy ED, et al
    Perspective of young breast cancer survivors (BCS) on fertility preservation (FP) referral.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  142. LI D
    Patterns of health care-related multimorbidity among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  143. TANO J, Conde FA
    Impact of chemotherapy on health-related quality of life among ethnically diverse breast cancer survivors treated with breast-conserving therapy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  144. HOCKING WG, Wiegmann D, Yen TY, Gribble M, et al
    Evaluation of electronic care plan usage and usefulness among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  145. TSUCHIYA K, Nishijima C, Suzuki N, Tsugawa K, et al
    Our act on fertility preservation for young breast cancer patients in our single institute.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  146. ABRAHAMSE P, Friese CR, Katz SJ, Hawley ST, et al
    Primary care provider engagement about breast cancer care during treatment: Results from the iCanCare Study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  147. PIACENTINE LB, Robinson KM, Ng AV, Waltke LJ, et al
    Underserved community-based walking program for breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  148. ZHENG L, Graves KD, Hurtado-de-Mendoza A, Tadasse M, et al
    Opportunities for precision medicine: Factors associated with participation in genetic research among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  149. GROOME P, Turner D, Jorgensen M, Kendell C, et al
    Using Canadian administrative data to evaluate primary and oncology care of breast cancer patients post-treatment: Subset of the CanIMPACT Study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  150. COLLEONI M, Sun Z, Price KN, Karlsson P, et al
    Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
    J Clin Oncol. 2016 Jan 19. pii: JCO623504.
    PubMed     Text format     Abstract available


  151. HENSON KE, Jagsi R, Cutter D, McGale P, et al
    Inferring the Effects of Cancer Treatment: Divergent Results From Early Breast Cancer Trialists' Collaborative Group Meta-Analyses of Randomized Trials and Observational Data From SEER Registries.
    J Clin Oncol. 2016 Jan 19. pii: JCO620294.
    PubMed     Text format     Abstract available


  152. THOMPSON ER, Rowley SM, Li N, McInerny S, et al
    Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
    J Clin Oncol. 2016 Jan 19. pii: JCO637454.
    PubMed     Text format     Abstract available


  153. NEWMAN LA
    Parsing the Etiology of Breast Cancer Disparities.
    J Clin Oncol. 2016 Jan 19. pii: JCO651877.
    PubMed     Text format    


  154. LOI S, Savas P
    Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2 -Positive Breast Cancer: Can We Understand It Better?
    J Clin Oncol. 2016 Jan 11. pii: JCO647495.
    PubMed     Text format    


  155. LICHTMAN SM, Cirrincione CT, Hurria A, Jatoi A, et al
    Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
    J Clin Oncol. 2016 Jan 11. pii: JCO626341.
    PubMed     Text format     Abstract available


  156. BELLET M, Gray KP, Francis PA, Lang I, et al
    Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
    J Clin Oncol. 2016 Jan 4. pii: JCO612259.
    PubMed     Text format     Abstract available


  157. DOWSETT M, Lonning PE, Davidson NE
    Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
    J Clin Oncol. 2016 Jan 4. pii: JCO623728.
    PubMed     Text format    


    December 2015
  158. GOODWIN PJ
    Obesity and Breast Cancer Outcomes: How Much Evidence Is Needed to Change Practice?
    J Clin Oncol. 2015 Dec 28. pii: JCO647503.
    PubMed     Text format    


  159. HENDERSON TO, Moskowitz CS, Chou JF, Bradbury AR, et al
    Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2015 Dec 23. pii: JCO623314.
    PubMed     Text format     Abstract available


  160. SLEDGE GW JR
    Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure.
    J Clin Oncol. 2015 Dec 23. pii: JCO647511.
    PubMed     Text format    


  161. VAN DEN BROEK AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, et al
    Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    J Clin Oncol. 2015 Dec 23. pii: JCO623942.
    PubMed     Text format     Abstract available


  162. JOHNSTON SR
    Targeted Combinations for Hormone Receptor-Positive Advanced Breast Cancer: Who Benefits?
    J Clin Oncol. 2015 Dec 23. pii: JCO.2015.64.0771.
    PubMed     Text format    


  163. RUNOWICZ CD, Leach CR, Henry NL, Henry KS, et al
    American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
    J Clin Oncol. 2015 Dec 7. pii: JCO.2015.64.3809.
    PubMed     Text format     Abstract available


  164. OGUZ A, Keskin GS, Colak D, Altundag O, et al
    Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer.
    J Clin Oncol. 2015 Dec 7. pii: JCO638411.
    PubMed     Text format    


  165. FERGUSON CM, Swaroop MN, Horick N, Skolny MN, et al
    Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer.
    J Clin Oncol. 2015 Dec 7. pii: JCO615948.
    PubMed     Text format     Abstract available


    November 2015
  166. HOLM J, Li J, Darabi H, Eklund M, et al
    Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis.
    J Clin Oncol. 2015 Nov 30. pii: JCO630624.
    PubMed     Text format     Abstract available


  167. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer.
    J Clin Oncol. 2015 Nov 30. pii: JCO629741.
    PubMed     Text format     Abstract available


  168. CLEMENS MW, Medeiros LJ, Butler CE, Hunt KK, et al
    Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
    J Clin Oncol. 2015 Nov 30. pii: JCO633412.
    PubMed     Text format     Abstract available


  169. ROBERTS MC, Weinberger M, Dusetzina SB, Dinan MA, et al
    Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
    J Clin Oncol. 2015 Nov 23. pii: JCO632489.
    PubMed     Text format     Abstract available


  170. KILLELEA BK, Yang VQ, Wang SY, Hayse B, et al
    Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Database.
    J Clin Oncol. 2015 Nov 23. pii: JCO637801.
    PubMed     Text format     Abstract available


  171. THORSEN LB, Offersen BV, Dano H, Berg M, et al
    DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer.
    J Clin Oncol. 2015 Nov 23. pii: JCO636456.
    PubMed     Text format     Abstract available


  172. HARRIGAN M, Cartmel B, Loftfield E, Sanft T, et al
    Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study.
    J Clin Oncol. 2015 Nov 23. pii: JCO616375.
    PubMed     Text format     Abstract available


  173. EPSTEIN AJ, Wong YN, Mitra N, Vachani A, et al
    Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
    J Clin Oncol. 2015 Nov 23. pii: JCO619023.
    PubMed     Text format     Abstract available


  174. SPAGNOLO F, Sestak I, Howell A, Forbes JF, et al
    Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
    J Clin Oncol. 2015 Nov 23. pii: JCO634972.
    PubMed     Text format     Abstract available


  175. LEVINE MN, Julian JA, Bedard PL, Eisen A, et al
    Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    J Clin Oncol. 2015 Nov 23. pii: JCO628503.
    PubMed     Text format     Abstract available


  176. PICCART-GEBHART M, Holmes E, Baselga J, de Azambuja E, et al
    Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
    J Clin Oncol. 2015 Nov 23. pii: JCO621797.
    PubMed     Text format     Abstract available


  177. FIORENTINO A, Mazzola R, Ricchetti F, Fersino S, et al
    Personalized-Not Omitted-Radiation Oncology for Breast Cancer.
    J Clin Oncol. 2015 Nov 2. pii: JCO.2015.62.9204.
    PubMed     Text format    


  178. PEREZ EA, Thompson EA, Ballman KV
    Reply to P.G. Gavin et al.
    J Clin Oncol. 2015;33:3672-3.
    PubMed     Text format    


    October 2015
  179. BEZJAK A, Ferguson SE
    Sex: Taboos, Assumptions, and Evidence.
    J Clin Oncol. 2015;33:3370-1.
    PubMed     Text format    


  180. YURGELUN MB, Hiller E, Garber JE
    Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
    J Clin Oncol. 2015;33:3092-5.
    PubMed     Text format    


  181. PALMER JB, Lane D, Mayo D, Schluchter M, et al
    Effects of Music Therapy on Anesthesia Requirements and Anxiety in Women Undergoing Ambulatory Breast Surgery for Cancer Diagnosis and Treatment: A Randomized Controlled Trial.
    J Clin Oncol. 2015;33:3162-8.
    PubMed     Text format     Abstract available


    September 2015
  182. GIANNI L, Arcangeli V, Tamburini E, Tassinari D, et al
    Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?
    J Clin Oncol. 2015 Sep 21. pii: JCO.2015.63.8726.
    PubMed     Text format    


  183. PANKRATZ VS, Degnim AC, Vierkant RA, Frank RD, et al
    Reply to M.H. Gail et al.
    J Clin Oncol. 2015;33:2830-1.
    PubMed     Text format    


  184. BALDO P, Fornasier G, Francescon S, Ferrarin E, et al
    Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance.
    J Clin Oncol. 2015;33:2824-5.
    PubMed     Text format    


  185. PERRONE F, Di Maio M, Gallo C
    Reply to P. Baldo et al.
    J Clin Oncol. 2015;33:2826.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: